Conatus launches IPO, price dips on first trading day
This article was originally published in Scrip
Conatus Pharmaceuticals had a rocky first day on the Nasdaq, since the company priced its initial public offering at $11 per share, but closed down 13.6% at $9.50.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.